NCT07142655View on ClinicalTrials.gov

An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs

Active, not recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Peripheral Arterial Disease (PAD)
Trial Locations (1)

101-0053

Medical Data Vision Co., Ltd, Tokyo

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT07142655 - An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs | Biotech Hunter | Biotech Hunter